AEYE Health and UMass Memorial Health (UMMH) integrated AEYE Health's AEYE-DS, an AI-based autonomous diagnostic screening solution, into UMMH's EMR system. The goals of this integration are to ...

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic ...

Aaron Nagial, MD, PhD, gave an interview discussing the work that he and the team at Children’s Hospital Los Angeles (CHLA) have been doing in the retinal gene therapy space. This interview comes at ...

Ray Kaczmarek joins Nanoscope Therapeutics as the company’s Chief Technology and Manufacturing Officer. Sulagna Bhattacharya, Co-founder and Chief Executive Officer of Nanoscope spoke to his Kaczmarek ...

This study was published online in the journal Aging Cell and reveals how DNA damage compromises the retina’s function and accelerates vision loss. Researchers have found that accumulated DNA damage ...

The aim of this program is to help advance junior clinical research scientists in their professional endeavors to cure retinal degenerative disease. The Foundation Fighting Blindness is inviting ...

Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes. Avant Technologies Inc.’s partner, Ainnova Tech, Inc., has entered a ...

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME). The results of a recent study indicated ...

The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a statistically significant improvement in time to treatment failure versus placebo as ...

Investigators from The Vision Center at the Children’s Hospital Los Angeles, and the Roski Eye Institute, Keck School of Medicine, University of Southern California, both in Los Angeles, reported that ...

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...